Courtesy of Benzinga.
Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced that it has filed a request for a temporary restraining order and preliminary injunction to prevent Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. from launching their enoxaparin sodium product in the United States.
Separately, on September 21, 2011 Momenta announced that it had sued Amphastar Pharmaceuticals, Inc., Watson Pharmaceuticals, Inc. and International Medical Systems, Ltd. in the United States District Court for the District of Massachusetts for infringement of two Momenta patents. The patents cover the company’s innovative methods of producing enoxaparin sodium, which assure that the commercial product meets standards for identity and quality. One patent, U.S. Patent No. 7,790,466, is related to methods of processing enoxaparin to determine the presence of certain tetrasaccharide structures. The second patent, U.S. Patent No. 7,575,886, is related to methods of analyzing enoxaparin for the presence of a certain structural signature.
